News from 2006

GlaxoSmithKline to acquire Domantis Ltd for $454million

GlaxoSmithKline plc (GSK) today announced that it has entered into an agreement to acquire Domantis Ltd for US$454million in cash.

Evotec Reaches First Milestone and Receives Success Payment in Alzheimer’s Disease Collaboration with Takeda

The first milestone in Evotec's four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited achieved.

PerkinElmer to Acquire Evotec Technologies

PerkinElmer have signed a definitive agreement to acquire Evotec Technologies in a transaction valued at approximately EUR23million. This agreement will allow Evotec to focus on core business drug discovery and development.

Aegerion Study Shows Combination Treatment With Aegr-733 And Zetia

Aegerion Pharmaceuticals, Inc. has announced interim results from its phase II clinical trial involving its lead cholesterol management compound, AEGR-733, alone and in combination with Zetia ®.

Evotec Announces Initiation of Phase I Clinic Trial with EVT 101

Evotec today announced initiation of a Phase I study with EVT 101, its NR2B subtype selective NMDA receptor antagonist for the potential treatment of Alzheimer’s disease, neuropathic pain and Parkinson’s disease.

Boehringer Ingelheim Extends Scope of Collaboration with Evotec into Screening Services

Boehringer extended scope of its collaboration with Evotec today.

Momenta Pharmaceuticals Commences Phase I Clinical Study for M118

Momenta Pharmaceuticals, Inc. announce that the Company has initiated dosing for its Phase I study.

Oxxon Therapeutics, Inc. Successfully Defends Challenge To Core Patent

Oxxon Therapeutics, Inc. successfully defends challenge to core patent.

Aegerion Pharmaceuticals Enters Into Cross License Agreement

Aegerion Pharmaceuticals, Inc. in collaboration with Pfizer, Inc. and the University of Pennsylvania, have entered into a cross-license relationship covering a range of patents related to the use of microsomal triglyceride transfer protein (MTP) inhibitors.

Clavis Pharma and Mount Sinai School of Medicine have entered into collaboration agreement for the development of new cancer drugs.

Collaborative development agreement on potential new cancer drugs between Clavis Pharma ASA and Mount Sinai School of Medicine.

Ardana Announces Positive Preliminary Phase II Results For Its Novel Testosterone Cream

Preliminary results of Ardana's testosterone cream in a Phase II study in hypogonadal men confirm that it is effective in restoring testosterone levels to the normal range.

Avantium provides Crystal 16TM to all research sites of Sanofi-Aventis

Avantium Technologies proprietary Crystal16™ will be deployed at all R&D centres of Sanofi-Aventis.

US Patent Granted to Ardana for Teverelix LA

Ardana announces that it has been granted a US patent, number 7,098,305, covering the long acting formulation of its GnRH antagonist, Teverelix (Teverelix LA).

Momenta Pharmaceuticals, Inc. has announced its financial results for 2Q ended 30 June 2006

Momenta Pharmaceuticals, Inc. has announced its financial results for 2Q ended 30 June 2006 - net loss was $12.6m ($4.6m net loss 2Q 05).

Evotec Successfully Completes Phase I for Potential Alzheimer’s Disease and Neuropathic Pain Treatment

Evotec AG today announced the successful completion of Phase I with EVT 101.

Momenta Pharmaceuticals Files Investigational New Drug Application for Novel Anticoagulant for Acute Coronary Syndromes

Momenta Pharmaceuticals, Inc. has submitted an electronic Investigational New Drug (IND) application to the U.S. Food and Drug Administration.

Momenta Pharmaceuticals and Sandoz Sign Exclusive Collaboration to Develop Complex Generics and Follow-On Versions of Biotechnology Drugs.

Momenta Pharmaceuticals, Inc. today announced an exclusive collaboration with Sandoz, the generics business of Novartis.

Argenta Discovery Announces New Drug Discovery Collaboration with AstraZeneca

Argenta Discovery Limited has announced that it has entered into a drug discovery collaboration with AstraZeneca LP.

DAC Selects Evotec as Strategic Partner for a Drug Discovery Collaboration on the HSP90 Cancer Target

DAC (a wholly owned subsidiary of Genextra SPA) has chosen Evotec AG as a strategic partner in a pharmaceutical discovery project.

Domantis First To Win UK Innovation In Drug Discovery & Development Award

Domantis is the first winner of the UK Innovation in Drug Discovery & Development Award.

Spherics and Takeda Enter Collaboration to Use Spherics’ Bioadhesive Technologies

Spherics, Inc. - Agreement Seeks to Improve Oral Performance of Takeda Compound Under Development.

Clavis Pharma ASA – Equity Offering

Clavis Pharma ASA's Board of Directors resolve to implement an Offer of new shares subsequent to the listing approval by the Oslo Børs Board of Directors.

Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs

Evotec and Roche alliance to jointly discover and develop compounds against a target for CNS diseases and other indications.

Domantis Granted Broad European Patent Rights To Pioneering Half-Life Extension Technology

Domantis announcement of grant with broad composition of matter claims protecting its "AlbudAb" technology.